Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
1.880
+0.060 (3.30%)
At close: Dec 20, 2024, 4:00 PM
1.970
+0.090 (4.79%)
After-hours: Dec 20, 2024, 5:56 PM EST
Sutro Biopharma Employees
Sutro Biopharma had 302 employees as of December 31, 2023. The number of employees increased by 24 or 8.63% compared to the previous year.
Employees
302
Change (1Y)
24
Growth (1Y)
8.63%
Revenue / Employee
$532,964
Profits / Employee
-$410,440
Market Cap
155.02M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
The Joint | 794 |
Adaptimmune Therapeutics | 449 |
Metagenomi | 236 |
Seres Therapeutics | 233 |
Cellectis | 221 |
Biomea Fusion | 103 |
Nanobiotix | 102 |
Corbus Pharmaceuticals Holdings | 19 |
STRO News
- 5 weeks ago - Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewsWire
- 6 weeks ago - Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - GlobeNewsWire
- 7 weeks ago - Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - GlobeNewsWire
- 2 months ago - Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewsWire
- 3 months ago - Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
- 3 months ago - Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024 - GlobeNewsWire
- 3 months ago - Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024 - GlobeNewsWire